Regulatory In Vitro Diagnostics Landscape in Africa: Update on Regional Activities.

Improved diagnostic tests for tuberculosis case detection are urgently needed that are affordable, robust, and easy to use so that they can be implemented widely. The mandate of national regulatory authorities is to ensure the safety and effectiveness of diagnostics, protecting the population against unsafe products while expediting access to beneficial new devices. However, regulatory approval processes in the developing world are often complex, lengthy, and not transparent. Recent progress in building regulatory capacity using harmonized approaches will reduce duplication in clinical performance studies and manufacturing audits, facilitate information sharing through trust and mutual confidence building, and ultimately improve efficiency. These savings can be passed onto the consumers in the form of more affordable pricing and allowing new high-quality tests for tuberculosis to be introduced more quickly and without delay.

[1]  J. Cunningham,et al.  New tuberculosis diagnostics and rollout. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[2]  R. S. Gupta,et al.  Feasibility of Decentralised Deployment of Xpert MTB/RIF Test at Lower Level of Health System in India , 2014, PloS one.

[3]  Ruth McNerney,et al.  Regulation of medical diagnostics and medical devices in the East African community partner states , 2014, BMC Health Services Research.

[4]  O. Lucas Adetokunho,et al.  Special Programme for Research and Training in Tropical Diseases (TDR) TDR- FINAL REPORT SERIES , 2001 .

[5]  Alimuddin Zumla,et al.  Impact of the Xpert MTB/RIF diagnostic test for tuberculosis in countries with a high burden of disease , 2015, Current opinion in pulmonary medicine.

[6]  Ruth McNerney,et al.  Emerging technologies in point-of-care molecular diagnostics for resource-limited settings , 2014, Expert review of molecular diagnostics.

[7]  L. Sechi,et al.  Clinical Utility of a Commercial LAM-ELISA Assay for TB Diagnosis in HIV-Infected Patients Using Urine and Sputum Samples , 2010, PloS one.

[8]  N. Dendukuri,et al.  Commercial Serological Tests for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis: An Updated Systematic Review and Meta-Analysis , 2011, PLoS medicine.

[9]  L. Gabbasova,et al.  Global tuberculosis report (2014) , 2014 .

[10]  R. Peeling,et al.  Improving access to new diagnostics through harmonised regulation: priorities for action , 2014, African journal of laboratory medicine.

[11]  Suvanand Sahu,et al.  Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries , 2014, BMC Infectious Diseases.

[12]  M. Hoelscher,et al.  Reasons for false-positive lipoarabinomannan ELISA results in a Tanzanian population , 2014, Scandinavian journal of infectious diseases.

[13]  A. Kesselheim,et al.  How Does Medical Device Regulation Perform in the United States and the European Union? A Systematic Review , 2012, PLoS medicine.

[14]  R. Hayes,et al.  Impact of HIV on tuberculosis in Zambia: a cross sectional study. , 1990, BMJ.